Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > A Way Out?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by zwerp2000on Feb 24, 2023 7:39am
82 Views
Post# 35302765

RE:RE:A Way Out?

RE:RE:A Way Out?Oh come on, no one is here...no one cares. Most sold out awhile ago. xb3 is junk. Yeah, i know you're tired of hearing me say that but it's just as tiresome to read posts that there is some conspiracy going on that xb3 is being stolen from shareholders. The company had years to sell this and couldn't.  Their last ditch attempt was selling xb3 for peanuts to a company that is practically bankrupt. No real company wanted to scoop this up for next to nothing which should tell you something. What's going on with Chiesi? Been about 3 years since the deal and not one update? I have to believe Chiesi assesed xb3 and decided not to progress with it.Game is over. The rest is just noise by the very few that are left here most likely just keep themselves entertained
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities